Top

06-09-2024 | Janus Kinase Inhibitors

Advances in Stem Cell Transplantation for Myelofibrosis

Authors: Akhil Rajendra, Vikas Gupta

Published in: Current Hematologic Malignancy Reports

Abstract

Purpose of Review

Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for myelofibrosis. This review discusses issues not well-covered by existing guidelines: timing of transplant, pre-transplant spleen management and alternative donors; providing our approach to these situations.

Recent Findings

Research continues to allow better identification, by better risk stratification and advances in understanding likelihood of durable JAKi response, which patients are likely to derive benefit from upfront transplant versus those for whom delayed transplant may be more appropriate. Several options of JAKi therapy provide a non-surgical option for pre-HCT splenomegaly management, allowing some patients to avoid risks associated with splenectomy. Recent years have also seen a sharp spike in haploidentical donor transplants, along with narrowing of the gap in outcomes between donor types.

Summary

Continuous enrollment in prospective studies or well-designed registries is required to generate the high-quality data needed to develop better decision tools for these scenarios.

Gangat N, Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol. 2020;191(2):152–70. https://doi.org/10.1111/bjh.16576.CrossRefPubMed

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in Myeloproliferative Neoplasms. New Eng J Med. 2018;379(15):1416–30. https://doi.org/10.1056/NEJMoa1716614.CrossRefPubMed

Bankar A, Gupta V. Investigational non-JAK inhibitors for chronic phase myelofibrosis. Expert Opin Investig Drugs. 2020;29(5):461–74. https://doi.org/10.1080/13543784.2020.1751121.CrossRefPubMed

Tvorogov D, Thompson-Peach CAL, Foßelteder J, Dottore M, Stomski F, Onnesha SA, et al. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. EMBO Rep. 2022;23(4):e52904. https://doi.org/10.15252/embr.202152904.CrossRefPubMedPubMedCentral

How J, Hobbs GS, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood. 2019;134(25):2242–8. https://doi.org/10.1182/blood.2019000622.CrossRefPubMedPubMedCentral

Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11(1):e62–74. https://doi.org/10.1016/s2352-3026(23)00305-8.

Polverelli N, Farina M, D’Adda M, Damiani E, Grazioli L, Leoni A, et al. How we manage myelofibrosis candidates for allogeneic stem cell transplantation. Cells. 2022;11(3). https://doi.org/10.3390/cells11030553.

Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management. Am J Hematol. 2024;99(5):938–45. https://doi.org/10.1002/ajh.27274.CrossRefPubMed

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8. https://doi.org/10.1182/blood-2009-09-245837.CrossRefPubMed

10.

Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7. https://doi.org/10.1200/jco.2010.32.2446.CrossRefPubMed

11.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310–8. https://doi.org/10.1200/jco.2017.76.4886.CrossRefPubMed

12.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–31. https://doi.org/10.1038/leu.2017.169.CrossRefPubMed

13.

Hernandez-Boluda JC, Pereira A, Correa JG, Alvarez-Larran A, Ferrer-Marin F, Raya JM, et al. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia. 2018;32(2):553–5. https://doi.org/10.1038/leu.2017.297.CrossRefPubMed

14.

Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347–50. https://doi.org/10.1182/blood-2014-10-608315.CrossRefPubMedPubMedCentral

15.

Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965–73. https://doi.org/10.1182/bloodadvances.2019001084.CrossRefPubMedPubMedCentral

16.

Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S et al. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024;59(2):196–202. https://doi.org/10.1038/s41409-023-02146-6.

17.

Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790–7. https://doi.org/10.1182/blood-2015-03-633404.CrossRefPubMedPubMedCentral

18.

Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Adv. 2017;1(20):1729–38. https://doi.org/10.1182/bloodadvances.2017009530.CrossRefPubMedPubMedCentral

19.

Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29(3):741–4. https://doi.org/10.1038/leu.2014.306.CrossRefPubMed

20.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs best available therapy, including Ruxolitinib, in patients with myelofibrosis: a Randomized Clinical Trial. JAMA Oncol. 2018;4(5):652–9. https://doi.org/10.1001/jamaoncol.2017.5818.CrossRefPubMedPubMedCentral

21.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73–81. https://doi.org/10.1016/s2352-3026(17)30237-5.CrossRefPubMed

22.

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269–80. https://doi.org/10.1016/s0140-6736(22)02036-0.CrossRefPubMed

23.

Smith E, Huang J, Viswabandya A, Maze D, Malik S, Cheung V, et al. Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus nontransplantation therapies in myelofibrosis. Transpl Cell Ther. 2021;27(7):600.e1-e8. https://doi.org/10.1016/j.jtct.2021.03.027.CrossRef

24.

Gupta V, Cerquozzi S, Foltz L, Hillis C, Devlin R, Elsawy M, et al. Patterns of Ruxolitinib Therapy failure and its management in myelofibrosis: perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncol Pract. 2020;16(7):351–9. https://doi.org/10.1200/jop.19.00506.CrossRefPubMedPubMedCentral

25.

England JT, Atenafu EG, Kennedy JA, Goraya B, Cheung V, Nye T, et al. Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor. Am J Hematol. 2023;98(5):E127–9. https://doi.org/10.1002/ajh.26890.

26.

Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96(1):69–79. https://doi.org/10.1002/ajh.26020.CrossRefPubMed

27.

Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise De Greffe De Moelle Et de Therapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331–9. https://doi.org/10.1111/j.1365-2141.2010.08417.x.CrossRefPubMed

28.

Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and marrow transplantation. Blood. 2009;114(26):5264–70. https://doi.org/10.1182/blood-2009-07-234880.CrossRefPubMed

29.

Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361–70. https://doi.org/10.1002/cncr.22021.CrossRefPubMed

30.

Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, et al. The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplantation. 2017;23(6):958–64. https://doi.org/10.1016/j.bbmt.2017.03.002.CrossRef

31.

Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45(3):458–63. https://doi.org/10.1038/bmt.2009.188.CrossRefPubMed

32.

Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D’Adda M, Deeg HJ, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10(1):e59–70. https://doi.org/10.1016/s2352-3026(22)00330-1.CrossRefPubMed

33.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. https://doi.org/10.1056/NEJMoa1110557.CrossRefPubMedPubMedCentral

34.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–98. https://doi.org/10.1056/NEJMoa1110556.CrossRefPubMed

35.

Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in patients with primary or secondary myelofibrosis: a Randomized Clinical Trial. JAMA Oncol. 2015;1(5):643–51. https://doi.org/10.1001/jamaoncol.2015.1590.CrossRefPubMed

36.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225–36. https://doi.org/10.1016/s2352-3026(17)30027-3.CrossRefPubMedPubMedCentral

37.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844–50. https://doi.org/10.1200/jco.2017.73.4418.CrossRefPubMedPubMedCentral

38.

Robin M, Porcher R, Orvain C, Bay JO, Barraco F, Huynh A, et al. Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transpl. 2021;56(8):1888–99. https://doi.org/10.1038/s41409-021-01252-7.CrossRef

39.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transpl. 2016;22(3):432–40. https://doi.org/10.1016/j.bbmt.2015.10.005.CrossRef

40.

Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transpl. 2014;49(2):179–84. https://doi.org/10.1038/bmt.2013.173.CrossRef

41.

Stubig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736–8. https://doi.org/10.1038/leu.2014.86.CrossRefPubMed

42.

Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, et al. Ruxolitinib Therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study. Biol Blood Marrow Transpl. 2019;25(2):256–64. https://doi.org/10.1016/j.bbmt.2018.09.001.CrossRef

43.

Salit RB, Scott BL, Stevens EA, Baker KK, Gooley TA, Deeg HJ. Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transpl. 2020;55(1):70–6. https://doi.org/10.1038/s41409-019-0523-3.CrossRef

44.

Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35(12):3551–60. https://doi.org/10.1038/s41375-021-01276-4.CrossRefPubMedPubMedCentral

45.

Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, et al. Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve patients with myelofibrosis: results of the MANIFEST-2 Randomized, Double-Blind, phase 3 study. Blood. 2023;142(Supplement 1):628. https://doi.org/10.1182/blood-2023-179141.CrossRef

46.

Pemmaraju N, Mead AJ, Somervaille TC, McCloskey JK, Palandri F, Koschmieder S, et al. Transform-1: a Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in patients with untreated myelofibrosis. Blood. 2023;142(Supplement 1):620. https://doi.org/10.1182/blood-2023-173509.CrossRef

47.

Harrison CN, Mesa RA, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F et al. Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study (Abstract #3204). American Society of Hematology Annual Meeting and Exposition 2023. San Diego, California.

48.

Gupta V, Yacoub A, Mesa R, Harrison CN, Vannucchi AM, Kiladijan JJ et al. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial. [In Press]. 2024.

49.

Harrison C, Kremyanskaya M, Bose P, Gupta V, Rampal RK, Lambert J, et al. Pelabresib (CPI-0610) as add-on to Ruxolitinib in Myelofibrosis: durability of response and safety beyond Week 24 in the phase 2 MANIFEST study. Blood. 2022;140(Supplement 1):9659–62. https://doi.org/10.1182/blood-2022-157735.CrossRef

50.

Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, et al. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy. J Clin Oncol. 2022;40(15):1671–80. https://doi.org/10.1200/jco.21.02188.CrossRefPubMedPubMedCentral

51.

Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis. Am J Hematol. 2024;99(5):844–53. https://doi.org/10.1002/ajh.27252.

52.

Jain T, Estrada-Merly N, Kim S, Salas MQ, Campos MA, Elmariah H, et al. Posttransplant cyclophosphamide-based transplantation from haploidentical donors has similar outcomes as unrelated donor transplantation in myelofibrosis: a center for international BMT research (CIBMTR) study. Transplant Cell Ther. 2023;29(2):S8–9. https://doi.org/10.1016/S2666-6367(23)00079-9.

53.

Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2014;20(1):89–97. https://doi.org/10.1016/j.bbmt.2013.10.018.CrossRef

54.

Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, et al. C[omparison of outcomes of Allogeneic Transplantation for Primary Myelofibrosis among hematopoietic stem cell source groups. Biol Blood Marrow Transpl. 2019;25(8):1536–43. https://doi.org/10.1016/j.bbmt.2019.02.019.CrossRef

Title: Advances in Stem Cell Transplantation for Myelofibrosis
Authors: Akhil Rajendra
Vikas Gupta
Publication date: 06-09-2024
Publisher: Springer US
Keywords: Janus Kinase Inhibitors
Ruxolitinib
Splenectomy
Splenectomy
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Current Hematologic Malignancy Reports
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-024-00742-x

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

12-09-2024
Type 1 Diabetes
News

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

12-09-2024
Obesity
News

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

12-09-2024
Type 2 Diabetes
News

Liraglutide reduces BMI for young children with obesity

11-09-2024
Pediatric Obesity
News

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Advances in Stem Cell Transplantation for Myelofibrosis

Abstract

Purpose of Review

Recent Findings

Summary

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

EASD 2024

2024 ESC Congress